Antibody light chain variable domains and their biophysically improved versions for human immunotherapy

mAbs

Volumn 6, Issue 1, 2014, Pages 219-235

  Kim, Dae Young ^a   To, Rebecca ^a   Kandalaft, Hiba ^a   Ding, Wen ^a   Van Faassen, Henk ^a   Luo, Yan ^a,e   Schrag, Joseph D ^a   St Amant, Nadereh ^b,f   Hefford, Mary ^b   Hirama, Tomoko ^a,g   Kelly, John F ^a   MacKenzie, Roger ^a,c   Tanha, Jamshid ^a,c,d  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b HEALTH CANADA   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Caprotec Bioanalytics GmbH   (Germany)

^f CANADIAN NUCLEAR SAFETY COMMISSION   (Canada)

^g NONE   (Japan)

Author keywords

Disulfide linkage; Protease resistance; Single domain antibody; Thermal stability; VL

Indexed keywords

ANTIBODY LIGHT CHAIN VARIABLE DOMAIN; DISULFIDE; IMMUNOMODULATING AGENT; PEPSIN A; SUPERANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; DISULFIDE BOND; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIGHT CHAIN; MELTING POINT; PHAGE DISPLAY; PROTEIN EXPRESSION; PROTEIN UNFOLDING; TEMPERATURE;

DISULFIDE LINKAGE; PROTEASE RESISTANCE; SINGLE-DOMAIN ANTIBODY; THERMAL STABILITY; VL;

ADMINISTRATION, ORAL; ESCHERICHIA COLI; HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN LIGHT CHAINS; PROTEIN STABILITY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84892619073     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26844     Document Type: Article

References (82)

1. Fox JL. Anthrax drug first antibacterial mAb to win approval. Nat Biotechnol 2013; 31:8; PMID:23302914; http://dx.doi.org/10.1038/ nbt0113-8
2. Nelson AL. Antibody fragments: hope and hype. MAbs 2010; 2:77-83; PMID:20093855; http:// dx.doi.org/10.4161/mabs.2.1.10786
3. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009; 27:331-7; PMID:19352366; http://dx.doi. org/10.1038/nbt0409-331
4. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36; PMID:16151406; http://dx.doi. org/10.1038/nbt1142 (Pubitemid 41486394)
5. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21:484-90; PMID:14573361; http://dx.doi.org/10.1016/j. tibtech.2003.08.007 (Pubitemid 37324200)
6. Ma X, Barthelemy PA, Rouge L, Wiesmann C, Sidhu SS. Design of synthetic autonomous VH domain libraries and structural analysis of a VH domain bound to vascular endothelial growth factor. J Mol Biol 2013; 425:2247-59; PMID:23507309; http:// dx.doi.org/10.1016/j.jmb.2013.03.020
7. Matz J, Kessler P, Bouchet J, Combes O, Ramos OH, Barin F, Baty D, Martin L, Benichou S, Chames P. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol 2013; 87:1137-49; PMID:23152508; http://dx.doi. org/10.1128/JVI.00461-12
8. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, et al. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One 2012; 7:e29941; PMID:22238680; http://dx.doi.org/10.1371/ journal. pone.0029941
9. Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Sharifzadeh Z. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. Exp Cell Res 2012; 318:1112-24; PMID:22440788; http://dx.doi.org/10.1016/j.yexcr.2012.03.004
10. Wei G, Meng W, Guo H, Pan W, Liu J, Peng T, Chen L, Chen CY. Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS One 2011; 6:e28309; PMID:22164266; http://dx.doi.org/10. 1371/journal. pone.0028309
11. Trilling AK, de Ronde H, Noteboom L, van Houwelingen A, Roelse M, Srivastava SK, Haasnoot W, Jongsma MA, Kolk A, Zuilhof H, et al. A broad set of different llama antibodies specific for a 16 kDa heat shock protein of Mycobacterium tuberculosis. PLoS One 2011; 6:e26754; PMID:22046343; http://dx.doi.org/10.1371/journal.pone.0026754
12. Skottrup PD, Leonard P, Kaczmarek JZ, Veillard F, Enghild JJ, O'Kennedy R, Sroka A, Clausen RP, Potempa J, Riise E. Diagnostic evaluation of a nanobody with picomolar affinity toward the protease RgpB from Porphyromonas gingivalis. Anal Biochem 2011; 415:158-67; PMID:21569755; http://dx.doi. org/10.1016/j.ab.2011.04.015
13. Goldman ER, Anderson GP, Zabetakis D, Walper S, Liu JL, Bernstein R, Calm A, Carney JP, O'Brien TW, Walker JL, et al. Llama-derived single domain antibodies specific for Abrus agglutinin. Toxins (Basel) 2011; 3:1405-19; PMID:22174977; http:// dx.doi.org/10.3390/toxins3111405
14. Emmerson CD, van der Vlist EJ, Braam MR, Vanlandschoot P, Merchiers P, de Haard HJW, Verrips CT, van Bergen en Henegouwen PM, Dolk E. Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH. PLoS One 2011; 6:e26299; PMID:22022593; http://dx.doi. org/10.1371/journal.pone.0026299
15. Hmila I, Saerens D, Ben Abderrazek R, Vincke C, Abidi N, Benlasfar Z, Govaert J, El Ayeb M, Bouhaouala-Zahar B, Muyldermans S. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J 2010; 24:3479-89; PMID:20410443; http://dx.doi.org/10.1096/ fj.09-148213
16. Monegal A, Ami D, Martinelli C, Huang H, Aliprandi M, Capasso P, Francavilla C, Ossolengo G, de Marco A. Immunological applications of singledomain llama recombinant antibodies isolated from a naïve library. Protein Eng Des Sel 2009; 22:273-80; PMID:19196718; http://dx.doi.org/10.1093/ protein/ gzp002
17. Li S, Zheng W, Kuolee R, Hirama T, Henry M, Makvandi-Nejad S, Fjällman T, Chen W, Zhang J. Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response. Mol Immunol 2009; 46:1718-26; PMID:19269688; http://dx.doi.org/10.1016/j.molimm.2009.02.007
18. Deckers N, Saerens D, Kanobana K, Conrath K, Victor B, Wernery U, Vercruysse J, Muyldermans S, Dorny P. Nanobodies, a promising tool for speciesspecific diagnosis of Taenia solium cysticercosis. Int J Parasitol 2009; 39:625-33; PMID:19041315; http:// dx.doi.org/10.1016/j.ijpara.2008.10.012
19. Abderrazek RB, Hmila I, Vincke C, Benlasfar Z, Pellis M, Dabbek H, Saerens D, El Ayeb M, Muyldermans S, Bouhaouala-Zahar B. Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. Biochem J 2009; 424:263-72; PMID:19732033; http://dx.doi. org/10.1042/BJ20090697
20. Koide A, Tereshko V, Uysal S, Margalef K, Kossiakoff AA, Koide S. Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar KD of a single-domain antibody with a flat paratope. J Mol Biol 2007; 373:941-53; PMID:17888451; http://dx.doi.org/10.1016/ j. jmb.2007.08.027 (Pubitemid 47498439)
21. Kopsidas G, Roberts AS, Coia G, Streltsov VA, Nuttall SD. In vitro improvement of a shark IgNAR antibody by Qß replicase mutation and ribosome display mimics in vivo affinity maturation. Immunol Lett 2006; 107:163-8; PMID:17069896; http:// dx.doi.org/10.1016/j.imlet.2006.09.004 (Pubitemid 44779820)
22. Shen J, Vil MD, Jimenez X, Iacolina M, Zhang H, Zhu Z. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J Biol Chem 2006; 281:10706-14; PMID:16481314; http://dx.doi.org/10.1074/jbc. M513415200 (Pubitemid 43855492)
23. Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM, Messer A, Lindquist S, Ingram VM, Wittrup KD. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A 2004; 101:17616-21; PMID:15598740; http://dx.doi.org/10.1073/ pnas.0408134101 (Pubitemid 40051935)
24. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H. Efficient cancer therapy with a nanobodybased conjugate. Cancer Res 2004; 64:2853-7; PMID:15087403; http://dx.doi.org/10.1158/ 0008-5472.CAN-03-3935 (Pubitemid 38500625)
25. Nuttall SD, Humberstone KS, Krishnan UV, Carmichael JA, Doughty L, Hattarki M, Coley AM, Casey JL, Anders RF, Foley M, et al. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 2004; 55:187-97; PMID:14997552; http://dx.doi. org/10.1002/prot.20005 (Pubitemid 38292846)
26. Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, Conrath K. Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem 2004; 279:51965-72; PMID:15459193; http:// dx.doi.org/10.1074/jbc. M409292200 (Pubitemid 39656566)
27. Nuttall SD, Krishnan UV, Doughty L, Pearson K, Ryan MT, Hoogenraad NJ, Hattarki M, Carmichael JA, Irving RA, Hudson PJ. Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. Eur J Biochem 2003; 270:3543-54; PMID:12919318; http://dx.doi.org/10.1046/j.1432-1033.2003.03737.x (Pubitemid 37046735)
28. Tanaka T, Lobato MN, Rabbitts TH. Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. J Mol Biol 2003; 331:1109-20; PMID:12927545; http://dx.doi.org/10. 1016/S0022-2836(03)00836-2 (Pubitemid 36969968)
29. Davies J, Riechmann L. Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding. Immunotechnology 1996; 2:169-79; PMID:9373310; http://dx.doi.org/10.1016/S1380- 2933(96)00045-0 (Pubitemid 26397525)
30. Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev 2005; 24:501-19; PMID:16408159; http://dx.doi.org/10.1007/s10555-005-6193-1 (Pubitemid 43096998)
31. Muyldermans S. Single domain camel antibodies: current status. J Biotechnol 2001; 74:277-302; PMID:11526908 (Pubitemid 34179619)
32. Hussack G, Keklikian A, Alsughayyir J, Hanifi-Moghaddam P, Arbabi-Ghahroudi M, van Faassen H, Hou ST, Sad S, MacKenzie R, Tanha J. A VL single-domain antibody library shows a high-propensity to yield non-aggregating binders. Protein Eng Des Sel 2012; 25:313-8; PMID:22490957; http://dx.doi. org/10.1093/protein/gzs014
33. Ewert S, Huber T, Honegger A, Plückthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325:531-53; PMID:12498801; http://dx.doi.org/10.1016/ S0022-2836(02)01237-8 (Pubitemid 36062681)
34. Dubnovitsky AP, Kravchuk ZI, Chumanevich AA, Cozzi A, Arosio P, Martsev SP. Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. Biochemistry (Mosc) 2000; 65:1011-8; PMID:11042491
35. Tomlinson IM, Cox JP, Gherardi E, Lesk AM, Chothia C. The structural repertoire of the human V? domain. EMBO J 1995; 14:4628-38; PMID:7556106
36. Lefranc MP. Nomenclature of the human immunoglobulin lambda (IGL) genes. Exp Clin Immunogenet 2001; 18:242-54; PMID:11872955; http://dx.doi. org/10.1159/000049203
37. Lefranc MP. Nomenclature of the human immunoglobulin kappa (IGK) genes. Exp Clin Immunogenet 2001; 18:161-74; PMID:11549845; http://dx.doi. org/10.1159/000049195
38. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wölle J, Plückthun A, Virnekäs B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000; 296:57-86; PMID:10656818; http://dx.doi.org/10.1006/ jmbi.1999.3444
39. Viau M, Longo NS, Lipsky PE, Björck L, Zouali M. Specific in vivo deletion of B-cell subpopulations expressing human immunoglobulins by the B-cell superantigen protein L. Infect Immun 2004; 72:3515-23; PMID:15155659; http://dx.doi. org/10.1128/IAI.72.6.3515-3523.2004 (Pubitemid 38697778)
40. Åkerström B, Nilson BH, Hoogenboom HR, Björck L. On the interaction between single chain Fv antibodies and bacterial immunoglobulinbinding proteins. J Immunol Methods 1994; 177:151-63; PMID:7822821; http://dx.doi. org/10.1016/0022-1759(94)90152-X
41. Nilson BH, Solomon A, Björck L, Åkerström B. Protein L from Peptostreptococcus magnus binds to the ? light chain variable domain. J Biol Chem 1992; 267:2234-9; PMID:1733930
42. Bork P, Holm L, Sander C. The immunoglobulin fold. Structural classification, sequence patterns and common core. J Mol Biol 1994; 242:309-20; PMID:7932691; http://dx.doi.org/10.1016/ S0022-2836(84)71582-8
43. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of Proteins of Immunological Interest, 5th ed., National Institutes of Health Publication 91-3242, National Institutes of Health, Bethesda, MD 1991.
44. Lesk AM, Chothia C. Evolution of proteins formed by ?-sheets. II. The core of the immunoglobulin domains. J Mol Biol 1982; 160:325-42; PMID:7175935; http://dx.doi.org/10.1016/0022-2836(82)90179-6 (Pubitemid 13239304)
45. Amzel LM, Poljak RJ. Three-dimensional structure of immunoglobulins. Annu Rev Biochem 1979; 48:961-97; PMID:89832; http://dx.doi.org/10.1146/ annurev.bi.48.070179.004525 (Pubitemid 10191101)
46. Kim DY, Kandalaft H, Ding W, Ryan S, van Faassen H, Hirama T, Foote SJ, MacKenzie R, Tanha J. Disulfide linkage engineering for improving biophysical properties of human VH domains. Protein Eng Des Sel 2012; 25:581-9; PMID:22942392; http:// dx.doi.org/10.1093/protein/gzs055
47. Kim DY, Ding W, Tanha J. Solubility and stability engineering of human VH domains. Methods Mol Biol 2012; 911:355-72; PMID:22886262
48. To R, Hirama T, Arbabi-Ghahroudi M, MacKenzie R, Wang P, Xu P, Ni F, Tanha J. Isolation of monomeric human VHs by a phage selection. J Biol Chem 2005; 280:41395-403; PMID:16221664; http:// dx.doi.org/10.1074/jbc.M509900200 (Pubitemid 41832198)
49. Hussack G, Hirama T, Ding W, Mackenzie R, Tanha J. Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS One 2011; 6:e28218; PMID:22140551; http://dx.doi. org/10.1371/journal.pone. 0028218
50. Saerens D, Conrath K, Govaert J, Muyldermans S. Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J Mol Biol 2008; 377:478-88; PMID:18262543; http://dx.doi.org/10.1016/ j.jmb.2008.01.022
51. Chan PH, Pardon E, Menzer L, De Genst E, Kumita JR, Christodoulou J, Saerens D, Brans A, Bouillenne F, Archer DB, et al. Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils. Biochemistry 2008; 47:11041-54; PMID:18816062; http://dx.doi.org/10.1021/bi8005797
52. Hagihara Y, Mine S, Uegaki K. Stabilization of an immunoglobulin fold domain by an engineered disulfide bond at the buried hydrophobic region. J Biol Chem 2007; 282:36489-95; PMID:17932041; http://dx.doi.org/10.1074/jbc.M707078200
53. Jespers L, Schon O, Famm K, Winter G. Aggregationresistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 2004; 22:1161-5; PMID:15300256; http://dx.doi.org/10.1038/ nbt1000 (Pubitemid 39166856)
54. Arbabi-Ghahroudi M, Mackenzie R, Tanha J. Site-directed mutagenesis for improving biophysical properties of VH domains. Methods Mol Biol 2010; 634:309-30; PMID:20676993; http://dx.doi. org/10.1007/978-1-60761-652-8-22
55. Arbabi-Ghahroudi M, To R, Gaudette N, Hirama T, Ding W, MacKenzie R, Tanha J. Aggregationresistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points. Protein Eng Des Sel 2009; 22:59-66; PMID:19033278; http://dx.doi.org/10.1093/ protein/gzn071
56. Wu SL, Jiang H, Lu Q, Dai S, Hancock WS, Karger BL. Mass spectrometric determination of disulfide linkages in recombinant therapeutic proteins using online LC-MS with electron-transfer dissociation. Anal Chem 2009; 81:112-22; PMID:19117448; http://dx.doi.org/10.1021/ac801560k
57. Schiefner A, Chatwell L, Körner J, Neumaier I, Colby DW, Volkmer R, Wittrup KD, Skerra A. A disulfidefree single-domain VL intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition. J Mol Biol 2011; 414:337-55; PMID:21968397; http://dx.doi.org/10.1016/j. jmb.2011.09.034
58. Lee WR, Jang JY, Kim JS, Kwon MH, Kim YS. Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies. Nucleic Acids Res 2010; 38:1596-609; PMID:20007602; http:// dx.doi.org/10.1093/ nar/gkp1145
59. Paz K, Brennan LA, Iacolina M, Doody J, Hadari YR, Zhu Z. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther 2005; 4:1801-9; PMID:16276002; http://dx.doi. org/10.1158/1535-7163.MCT-05-0174 (Pubitemid 41685315)
60. Colby DW, Garg P, Holden T, Chao G, Webster JM, Messer A, Ingram VM, Wittrup KD. Development of a human light chain variable domain (VL) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol 2004; 342:901-12; PMID:15342245; http://dx.doi. org/10.1016/j.jmb.2004.07.054 (Pubitemid 39165658)
61. van den Beucken T, van Neer N, Sablon E, Desmet J, Celis L, Hoogenboom HR, Hufton SE. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J Mol Biol 2001; 310:591-601; PMID:11439026; http://dx.doi.org/10.1006/jmbi.2001.4703 (Pubitemid 32692572)
62. Enever C, Tomlinson IM, Lund J, Levens M, Holliger P. Engineering high affinity superantigens by phage display. J Mol Biol 2005; 347:107-20; PMID:15733921; http://dx.doi.org/10.1016/j. jmb.2005.01.020 (Pubitemid 40283632)
63. Housden NG, Harrison S, Housden HR, Thomas KA, Beckingham JA, Roberts SE, Bottomley SP, Graille M, Stura E, Gore MG. Observation and characterization of the interaction between a single immunoglobulin binding domain of protein L and two equivalents of human ? light chains. J Biol Chem 2004; 279:9370-8; PMID:14668335; http://dx.doi. org/10.1074/jbc.M312938200 (Pubitemid 38296002)
64. Graille M, Stura EA, Housden NG, Beckingham JA, Bottomley SP, Beale D, Taussig MJ, Sutton BJ, Gore MG, Charbonnier JB. Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins. Structure 2001; 9:679-87; PMID:11587642; http://dx.doi. org/10.1016/S0969-2126(01)00630-X (Pubitemid 32772890)
65. Åkerström B, Björck L. Protein L: an immunoglobulin light chain-binding bacterial protein. Characterization of binding and physicochemical properties. J Biol Chem 1989; 264:19740-6; PMID:2479638 (Pubitemid 20008082)
66. Björck L. Protein L. A novel bacterial cell wall protein with affinity for Ig L chains. J Immunol 1988; 140:1194-7; PMID:3125250 (Pubitemid 18088588)
67. Stevens FJ, Westholm FA, Solomon A, Schiffer M. Self-association of human immunoglobulin ?I light chains: role of the third hypervariable region. Proc Natl Acad Sci U S A 1980; 77:1144-8; PMID:6767243; http://dx.doi.org/10.1073/ pnas.77.2.1144 (Pubitemid 10105073)
68. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A 2012; 109:10879-84; PMID:22745168; http://dx.doi.org/10.1073/pnas.1202866109
69. Gorlani A, Hulsik DL, Adams H, Vriend G, Hermans P, Verrips T. Antibody engineering reveals the important role of J segments in the production efficiency of llama single-domain antibodies in Saccharomyces cerevisiae. Protein Eng Des Sel 2012; 25:39-46; PMID:22143875; http://dx.doi.org/10.1093/ protein/gzr057
70. Tanha J, Nguyen TD, Ng A, Ryan S, Ni F, Mackenzie R. Improving solubility and refolding efficiency of human VHs by a novel mutational approach. Protein Eng Des Sel 2006; 19:503-9; PMID:16971398; http://dx.doi.org/10.1093/protein/ gzl037 (Pubitemid 44627323)
71. Svensson HG, Wedemeyer WJ, Ekstrom JL, Callender DR, Kortemme T, Kim DE, Sjöbring U, Baker D. Contributions of amino acid side chains to the kinetics and thermodynamics of the bivalent binding of protein L to Ig ? light chain. Biochemistry 2004; 43:2445-57; PMID:14992582; http://dx.doi. org/10.1021/bi034873s (Pubitemid 38327840)
72. Famm K, Hansen L, Christ D, Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol 2008; 376:926-31; PMID:18199455; http://dx.doi. org/10.1016/j.jmb.2007.10.075
73. Hubbard SJ, Beynon RJ, Thornton JM. Assessment of conformational parameters as predictors of limited proteolytic sites in native protein structures. Protein Eng 1998; 11:349-59; PMID:9681867; http://dx.doi. org/10.1093/protein/11.5.349 (Pubitemid 28279658)
74. Frenken LG, Egmond MR, Batenburg AM, Verrips CT. Pseudomonas glumae lipase: increased proteolytic stability by protein engineering. Protein Eng 1993; 6:637-42; PMID:8234234; http://dx.doi. org/10.1093/protein/6.6.637 (Pubitemid 23246515)
75. Christ D, Famm K, Winter G. Repertoires of aggregation-resistant human antibody domains. Protein Eng Des Sel 2007; 20:413-6; PMID:17720749; http://dx.doi.org/10.1093/protein/gzm037 (Pubitemid 47428968)
76. McConnell AD, Spasojevich V, Macomber JL, Krapf IP, Chen A, Sheffer JC, Berkebile A, Horlick RA, Neben S, King DJ, et al. An integrated approach to extreme thermostabilization and affinity maturation of an antibody. Protein Eng Des Sel 2013; 26:151-64; PMID:23173178; http://dx.doi.org/10.1093/ protein/gzs090
77. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends JW, Hoogenboom HR. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274:18218-30; PMID:10373423; http://dx.doi.org/10.1074/jbc.274.26.18218
78. Sblattero D, Bradbury A. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology 1998; 3:271-8; PMID:9530560; http://dx.doi.org/10.1016/S1380-2933(97)10004-5 (Pubitemid 28098329)
79. Tanha J, Muruganandam A, Stanimirovic D. Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol Med 2003; 89:435-49; PMID:12958438
80. Dombkowski AA. Disulfide by DesignTM: a computational method for the rational design of disulfide bonds in proteins. Bioinformatics 2003; 19:1852-3; PMID:14512360; http://dx.doi.org/10.1093/ bioinformatics/btg231 (Pubitemid 37220480)
81. Baral TN, Chao SY, Li S, Tanha J, Arbabi-Ghahroudi M, Zhang J, Wang S. Crystal structure of a human single domain antibody dimer formed through VH-VH non-covalent interactions. PLoS One 2012; 7:e30149; PMID:22253912; http://dx.doi.org/10.1371/journal. pone.0030149
82. Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, Charbonnier JB, Silverman GJ. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci U S A 2000; 97:5399-404; PMID:10805799; http://dx.doi.org/10.1073/pnas.97.10.5399 (Pubitemid 30313730)